{"id":"ac2993","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Gastrointestinal disorders"}]},"_chembl":{"chemblId":"CHEMBL414357","moleculeType":"Protein","molecularWeight":"4186.64"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By simultaneously stimulating GLP-1 and GIP receptors, AC2993 enhances insulin secretion in response to glucose, slows gastric emptying, and increases satiety signaling in the brain. This dual mechanism produces greater reductions in blood glucose and body weight compared to GLP-1 monotherapy, making it potentially more effective for type 2 diabetes and obesity management.","oneSentence":"AC2993 is a dual GLP-1/GIP receptor agonist that activates both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors to improve glycemic control and promote weight loss.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:58:39.647Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Obesity or weight management"}]},"trialDetails":[{"nctId":"NCT07497399","phase":"PHASE2","title":"Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-04","conditions":"Multiple Sclerosis","enrollment":120},{"nctId":"NCT05610800","phase":"PHASE2","title":"Exenatide for Smoking Cessation and Prevention of Weight Gain","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2022-12-07","conditions":"Smoking Cessation, Weight Gain","enrollment":140},{"nctId":"NCT05663515","phase":"","title":"A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-09-30","conditions":"Pancreatic Cancer","enrollment":24000},{"nctId":"NCT06252623","phase":"PHASE1","title":"Exenatide For Reducing the Reinforcing Effects of Cocaine","status":"WITHDRAWN","sponsor":"Christopher D. Verrico","startDate":"2024-08-01","conditions":"Cocaine Use Disorder","enrollment":""},{"nctId":"NCT05356104","phase":"PHASE2","title":"GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2022-05-25","conditions":"Cerebral Small Vessel Disease","enrollment":110},{"nctId":"NCT02251431","phase":"PHASE3","title":"Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2015-11","conditions":"Type 2 Diabetes Mellitus, Chronic Kidney Disease, Left Ventricular Diastolic Dysfunction","enrollment":57},{"nctId":"NCT04897802","phase":"PHASE4","title":"Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2021-09-13","conditions":"Hypopituitarism, Central Diabetes Insipidus, Panhypopituitarism","enrollment":42},{"nctId":"NCT07347080","phase":"EARLY_PHASE1","title":"A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes Mellitus","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Henan University of Science and Technology","startDate":"2026-01-13","conditions":"T2DM","enrollment":9},{"nctId":"NCT07340437","phase":"","title":"Clinical Study of 18F-Exendin-4 in Insulinoma","status":"COMPLETED","sponsor":"Sichuan Provincial People's Hospital","startDate":"2023-02-01","conditions":"Insulinoma","enrollment":20},{"nctId":"NCT02586831","phase":"PHASE1, PHASE2","title":"Diabetes Islet Preservation Immune Treatment","status":"WITHDRAWN","sponsor":"Camillo Ricordi and Jay Skyler","startDate":"2024-06-01","conditions":"Diabetes Mellitus, Type 1, Hypoglycemia, Autoimmune Diseases","enrollment":""},{"nctId":"NCT05482789","phase":"PHASE4","title":"Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes","status":"RECRUITING","sponsor":"Maisa N. Feghali, MD","startDate":"2023-04-12","conditions":"Gestational Diabetes","enrollment":13},{"nctId":"NCT04520490","phase":"PHASE3","title":"Brain Activation and Satiety in Children 2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seattle Children's Hospital","startDate":"2021-01-28","conditions":"Childhood Obesity","enrollment":63},{"nctId":"NCT07309094","phase":"","title":"Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD","status":"RECRUITING","sponsor":"Cardenal Herrera University","startDate":"2023-09-15","conditions":"Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 1","enrollment":250},{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT05073692","phase":"","title":"Comparison of Type 2 Diabetes Pharmacotherapy Regimens","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2021-07-01","conditions":"Type 2 Diabetes Mellitus, Cardiovascular Diseases","enrollment":241981},{"nctId":"NCT05670379","phase":"PHASE1","title":"Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant","status":"COMPLETED","sponsor":"Vivani Medical, Inc","startDate":"2024-12-20","conditions":"Overweight and Obesity, Type2diabetes","enrollment":24},{"nctId":"NCT07188545","phase":"","title":"Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ohio State University","startDate":"2025-09-15","conditions":"Cardiovascular Kidney Metabolic Syndrome","enrollment":23280000},{"nctId":"NCT06254014","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Dongfang Biotech Co., Ltd.","startDate":"2024-07-10","conditions":"Type 2 Diabetes Mellitus","enrollment":270},{"nctId":"NCT06256419","phase":"NA","title":"Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DM","status":"RECRUITING","sponsor":"The Affiliated Hospital of Xuzhou Medical University","startDate":"2024-01-01","conditions":"Type 2 Diabetes Mellitus, Susceptibility, Genetic","enrollment":300},{"nctId":"NCT06257966","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Dongfang Biotech Co., Ltd.","startDate":"2024-07-17","conditions":"Type2 Diabetes Mellitus","enrollment":600},{"nctId":"NCT05762744","phase":"PHASE1","title":"Pharmacogenomics of GLP1 Receptor Agonists","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2016-06-01","conditions":"Type 2 Diabetes","enrollment":63},{"nctId":"NCT04431713","phase":"PHASE2","title":"Exenatide Once-weekly as a Treatment for Multiple System Atrophy","status":"COMPLETED","sponsor":"University College, London","startDate":"2020-09-16","conditions":"Multiple System Atrophy","enrollment":50},{"nctId":"NCT03492580","phase":"","title":"A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-22","conditions":"Diabetes Mellitus, Type 2, Cardiovascular Diseases","enrollment":714582},{"nctId":"NCT06888167","phase":"NA","title":"Food (poly)phenol Metabotypes and Beta-cell Mass and Function.","status":"RECRUITING","sponsor":"Azienda Ospedaliero-Universitaria di Parma","startDate":"2024-10-14","conditions":"Healthy Volunteer","enrollment":40},{"nctId":"NCT05662189","phase":"NA","title":"Assessment of Pancreatic Beta Cell Mass and Function by Positron Emission Tomography Imaging in Human Diabetes Mellitus","status":"RECRUITING","sponsor":"Azienda Ospedaliero-Universitaria di Parma","startDate":"2022-03-15","conditions":"Type1diabetes, Type2diabetes, Pre Diabetes","enrollment":70},{"nctId":"NCT06725693","phase":"","title":"Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease","status":"RECRUITING","sponsor":"Tianjin Medical University","startDate":"2019-02-01","conditions":"GLP1-R-related Disease, Tumor, Insulinoma","enrollment":500},{"nctId":"NCT00679042","phase":"PHASE3","title":"Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol","status":"ACTIVE_NOT_RECRUITING","sponsor":"CellTrans Inc.","startDate":"2007-09-05","conditions":"Type 1 Diabetes Mellitus","enrollment":21},{"nctId":"NCT04154072","phase":"PHASE2","title":"A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease","status":"COMPLETED","sponsor":"Neuraly, Inc.","startDate":"2020-02-27","conditions":"Parkinson Disease","enrollment":255},{"nctId":"NCT04307797","phase":"PHASE4","title":"Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 Diabetes","status":"COMPLETED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2022-01-18","conditions":"Type 2 Diabetes, Obesity","enrollment":10},{"nctId":"NCT01107717","phase":"PHASE4","title":"Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2009-01","conditions":"Diabetes","enrollment":318},{"nctId":"NCT02673931","phase":"NA","title":"GLP-1 and Hyperoxia for Organ Protection in Heart Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2016-02","conditions":"Coronary Disease, Shock, Cardiogenic, Renal Failure","enrollment":1400},{"nctId":"NCT06247748","phase":"PHASE1","title":"Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese Subjects","status":"COMPLETED","sponsor":"Beijing Dongfang Biotech Co., Ltd.","startDate":"2023-10-19","conditions":"Diabetes Mellitus, Type 2, Overweight","enrollment":28},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT02157974","phase":"PHASE2, PHASE3","title":"Liver and Fat Regulation in Overweight Adolescent Girls","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2014-08","conditions":"Hepatic Steatosis, Polycystic Ovarian Syndrome, Obesity","enrollment":92},{"nctId":"NCT03923114","phase":"NA","title":"Imaging Pituitary ActiVation by Exendin","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2019-05-23","conditions":"Diabetes Mellitus, Type 2","enrollment":20},{"nctId":"NCT04909333","phase":"NA","title":"Exenatide-test for Diagnosing Endogenous Hyperinsulinemic Hypoglycemia","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2021-04-29","conditions":"Endogenous Hyperinsulinism","enrollment":29},{"nctId":"NCT05347147","phase":"PHASE3","title":"A Trial to Determine the Efficacy and Safety of Presendin in IIH","status":"TERMINATED","sponsor":"Invex Therapeutics Ltd.","startDate":"2022-11-18","conditions":"Idiopathic Intracranial Hypertension","enrollment":14},{"nctId":"NCT03029351","phase":"PHASE4","title":"GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes","status":"TERMINATED","sponsor":"University at Buffalo","startDate":"2017-01-10","conditions":"Type2 Diabetes, Kidney Diseases","enrollment":15},{"nctId":"NCT03835013","phase":"NA","title":"Haemodynamic Effects of GLP-1 and Glucagon in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2019-02-11","conditions":"Cardiovascular Diseases","enrollment":26},{"nctId":"NCT02962492","phase":"NA","title":"An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2016-11-01","conditions":"Evaluate Ketogenic Stress","enrollment":70},{"nctId":"NCT05136287","phase":"","title":"SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY.","status":"COMPLETED","sponsor":"Jose Seijas Amigo","startDate":"2022-02-01","conditions":"Weight Loss, Diabetes Mellitus, Type 2, Quality of Life","enrollment":140},{"nctId":"NCT03182296","phase":"NA","title":"Visualizing Beta Cells in Patients With a History of Gestational Diabetes","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2016-11-10","conditions":"Gestational Diabetes","enrollment":24},{"nctId":"NCT01524705","phase":"PHASE4","title":"FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)","status":"COMPLETED","sponsor":"University of Washington","startDate":"2012-08","conditions":"Type 2 Diabetes","enrollment":102},{"nctId":"NCT04232969","phase":"PHASE3","title":"Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease","status":"UNKNOWN","sponsor":"University College, London","startDate":"2020-01-20","conditions":"Parkinson's Disease","enrollment":194},{"nctId":"NCT04615910","phase":"PHASE2","title":"A GLP-1 Receptor PET Imaging Substudy Within the VER-A-T1D Trial Investigating the Effects on Beta Cell Mass","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2021-07-01","conditions":"Diabetes Mellitus","enrollment":30},{"nctId":"NCT03182192","phase":"PHASE1","title":"GLP1R-imaging in Hypoglycemia","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2016-04-01","conditions":"Hypoglycemia","enrollment":12},{"nctId":"NCT05418907","phase":"","title":"Exendin PET/CT for Imaging of Paragangliomas","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2022-06-01","conditions":"Paraganglioma","enrollment":10},{"nctId":"NCT03151005","phase":"PHASE4","title":"The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS","status":"COMPLETED","sponsor":"Xinqiao Hospital of Chongqing","startDate":"2017-07-01","conditions":"Polycystic Ovary Syndrome (PCOS), Overweight, Obesity","enrollment":70},{"nctId":"NCT04979611","phase":"PHASE1","title":"The Clinical Application of 68Ga-NOTA-exendin-4 PET/CT in Detecting Insulinoma","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Fujian Medical University","startDate":"2020-08-01","conditions":"Insulinoma","enrollment":60},{"nctId":"NCT04504396","phase":"PHASE3","title":"Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy","status":"COMPLETED","sponsor":"PegBio Co., Ltd.","startDate":"2020-06-23","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":620},{"nctId":"NCT04504370","phase":"PHASE3","title":"Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects","status":"COMPLETED","sponsor":"PegBio Co., Ltd.","startDate":"2020-04-27","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":273},{"nctId":"NCT03331289","phase":"PHASE4","title":"Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2018-02-28","conditions":"Diabetes Mellitus, Type 2","enrollment":107},{"nctId":"NCT02981069","phase":"PHASE4","title":"Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2017-12-15","conditions":"Diabetes Mellitus, Type 2","enrollment":90},{"nctId":"NCT03889496","phase":"NA","title":"Quantitative GLP-1 Receptor Imaging Correlated to ex Vivo Distribution of In-111-exendin","status":"TERMINATED","sponsor":"Radboud University Medical Center","startDate":"2015-11-16","conditions":"Diabetes Mellitus","enrollment":12},{"nctId":"NCT01364584","phase":"NA","title":"Impact of Exenatide on Cardiovascular Exercise Performance in Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2010-10","conditions":"Type 2 Diabetes","enrollment":23},{"nctId":"NCT05161429","phase":"","title":"BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-07-01","conditions":"Diabetes Mellitus, Type 2","enrollment":550000},{"nctId":"NCT01511393","phase":"","title":"An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)","status":"ENROLLING_BY_INVITATION","sponsor":"Novo Nordisk A/S","startDate":"2012-01","conditions":"Diabetes, Diabetes Mellitus, Type 2, Medullary Thyroid Carcinoma","enrollment":6750},{"nctId":"NCT01416649","phase":"","title":"Impact of Exenatide on Sleep Duration","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2011-02-01","conditions":"Type 2 Diabetes","enrollment":8},{"nctId":"NCT02621489","phase":"PHASE4","title":"Effects on Re-endothelialisation With Bydureon Treatment in Type 2 Diabetes Subjects","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2015-12","conditions":"Atherosclerosis, Diabetes, Restenosis","enrollment":38},{"nctId":"NCT05622123","phase":"PHASE2","title":"BetaFIT Study: Beta Cell Imaging After Faecal mIcrobiota Transplantation","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2023-02-23","conditions":"Type 1 Diabetes","enrollment":20},{"nctId":"NCT02829502","phase":"PHASE2","title":"The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Stroke","status":"UNKNOWN","sponsor":"Christina Kruuse","startDate":"2016-08","conditions":"Ischemic Stroke","enrollment":30},{"nctId":"NCT02244164","phase":"NA","title":"Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.","status":"TERMINATED","sponsor":"Erasme University Hospital","startDate":"2014-10","conditions":"Type 2 Diabetes, Incretinomimetics, Pancreas","enrollment":5},{"nctId":"NCT02302976","phase":"PHASE1","title":"GLP-1 Agonism for Blocking Cocaine Euphoria and Self-Administration","status":"COMPLETED","sponsor":"Yale University","startDate":"2014-11","conditions":"Cocaine Dependence","enrollment":13},{"nctId":"NCT03961256","phase":"PHASE2","title":"Assess the Efficacy and Safety of Exenatide SR for the Prevention of Diabetes After Kidney Transplantation","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2019-05-09","conditions":"Pre Diabetes","enrollment":9},{"nctId":"NCT05034783","phase":"EARLY_PHASE1","title":"[68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-10-01","conditions":"Insulinoma","enrollment":20},{"nctId":"NCT01154933","phase":"PHASE2","title":"Exeantide in Type 2 Diabetes on Insulin","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2008-04","conditions":"Type 2 Diabetes","enrollment":24},{"nctId":"NCT03456687","phase":"PHASE1","title":"Effects of Exenatide on Motor Function and the Brain","status":"COMPLETED","sponsor":"University of Florida","startDate":"2018-06-05","conditions":"Parkinson's Disease","enrollment":5},{"nctId":"NCT04305002","phase":"PHASE2","title":"Exenatide Treatment in Parkinson's Disease","status":"UNKNOWN","sponsor":"Center for Neurology, Stockholm","startDate":"2020-01-21","conditions":"Parkinson Disease","enrollment":60},{"nctId":"NCT04941521","phase":"PHASE1, PHASE2","title":"Exenatide for Treating Cocaine Use Disorder","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2021-06-24","conditions":"Cocaine Use Disorder","enrollment":3},{"nctId":"NCT03182231","phase":"PHASE1, PHASE2","title":"GLP1-imaging Before and After Bariatric Surgery","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2016-10-07","conditions":"Diabetes Mellitus, Type 2, Bariatric Surgery Candidate","enrollment":12},{"nctId":"NCT00775684","phase":"NA","title":"Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2008-10","conditions":"Pre-diabetes, Type 2 Diabetes","enrollment":47},{"nctId":"NCT02794402","phase":"PHASE2","title":"Double-blinded, 6 Months Study With Bydureon® or Placebo in Adolescents With Obesity to Explore Changes in BMI","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2015-09","conditions":"Obesity","enrollment":44},{"nctId":"NCT02664441","phase":"PHASE3","title":"Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity","status":"COMPLETED","sponsor":"Seattle Children's Hospital","startDate":"2016-03","conditions":"Hypothalamic Obesity","enrollment":42},{"nctId":"NCT03350191","phase":"PHASE1","title":"A Clinical Study to Investigate if SAR425899 Binds to the Liver and Pancreas in Overweight to Obese Type 2 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-12-20","conditions":"Type 2 Diabetes Mellitus","enrollment":13},{"nctId":"NCT03007329","phase":"PHASE4","title":"Effects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2017-03-08","conditions":"Steatosis, Liver, Type2 Diabetes","enrollment":34},{"nctId":"NCT04969627","phase":"PHASE4","title":"Effects of GLP-1 Analogue Combined With Metformin and Metformin on Gonadal and Metabolic Profiles in Chinese Overweight/Obese PCOS Patients With Hyperandrogenemia.","status":"COMPLETED","sponsor":"Bing He","startDate":"2021-01-04","conditions":"Polycystic Ovary Syndrome","enrollment":60},{"nctId":"NCT05328843","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetic Characteristics of Pegylated Exenatide Injection (PB-119) in Subjects With Different Degrees of Renal Insufficiency and Matched Subjects With Normal Renal Function","status":"UNKNOWN","sponsor":"PegBio Co., Ltd.","startDate":"2022-05-01","conditions":"Type2Diabetes","enrollment":24},{"nctId":"NCT02194595","phase":"PHASE3","title":"Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)","status":"COMPLETED","sponsor":"Mount Sinai Hospital, Canada","startDate":"2014-09","conditions":"Type 2 Diabetes","enrollment":105},{"nctId":"NCT01302327","phase":"NA","title":"GLP Analogs for Diabetes in Wolfram Syndrome Patients","status":"WITHDRAWN","sponsor":"Hadassah Medical Organization","startDate":"2011-03-01","conditions":"Diabetes Mellitus Associated With Genetic Syndrome, Wolfram Syndrome","enrollment":""},{"nctId":"NCT02787551","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-07-06","conditions":"Type 2 Diabetes Mellitus","enrollment":514},{"nctId":"NCT03645408","phase":"PHASE1","title":"The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy Drinkers","status":"TERMINATED","sponsor":"Boston Medical Center","startDate":"2019-05-02","conditions":"Alcohol Use Disorder","enrollment":8},{"nctId":"NCT00882050","phase":"PHASE1, PHASE2","title":"Intravenous Exenatide (Byetta) During Surgery","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2009-03","conditions":"Euglycemia, Hypoglycemia, Hyperglycemia","enrollment":104},{"nctId":"NCT02417142","phase":"PHASE4","title":"Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia","status":"COMPLETED","sponsor":"University of Massachusetts, Worcester","startDate":"2014-09","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":70},{"nctId":"NCT02496611","phase":"PHASE2","title":"Enhancing Weight Loss Maintenance With GLP-1RA (BYDUREON™) in Adolescents With Severe Obesity","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2015-12","conditions":"Severe Obesity","enrollment":100},{"nctId":"NCT01554618","phase":"PHASE3","title":"Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-12-02","conditions":"Children and Adolescent With Type 2 Diabetes","enrollment":84},{"nctId":"NCT03287076","phase":"PHASE2","title":"Trial of EXenatide in Acute Ischaemic Stroke","status":"UNKNOWN","sponsor":"Neuroscience Trials Australia","startDate":"2017-11-23","conditions":"Acute Ischemic Stroke","enrollment":350},{"nctId":"NCT03970044","phase":"PHASE4","title":"Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.","status":"COMPLETED","sponsor":"Consano Clinical Research, LLC","startDate":"2019-07-02","conditions":"Diabetes Mellitus, Type 2","enrollment":67},{"nctId":"NCT02847403","phase":"PHASE3","title":"Long-acting Exenatide and Cognitive Decline in Dysglycemic Patients","status":"UNKNOWN","sponsor":"Azienda Ospedaliero-Universitaria di Parma","startDate":"2016-02","conditions":"Dysglycemia, Cognitive Deficit","enrollment":40},{"nctId":"NCT01269034","phase":"PHASE4","title":"New Onset Type 1 Diabetes: Role of Exenatide","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2010-12","conditions":"Type 1 Diabetes","enrollment":13},{"nctId":"NCT01590433","phase":"PHASE4","title":"Weight Loss With Exenatide Treatment","status":"COMPLETED","sponsor":"Jody Dushay","startDate":"2012-03","conditions":"Obesity","enrollment":249},{"nctId":"NCT03189953","phase":"PHASE1, PHASE2","title":"68Ga-NODAGA-exendin-4 PET/CT for Diagnostic Imaging in AHH","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2015-04","conditions":"Insulinoma","enrollment":56},{"nctId":"NCT03361098","phase":"PHASE4","title":"DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2017-09-18","conditions":"Type 2 Diabetes Mellitus, Obesity","enrollment":65},{"nctId":"NCT03232112","phase":"PHASE2","title":"Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?","status":"COMPLETED","sponsor":"Anders Fink-Jensen, MD, DMSci","startDate":"2017-08-07","conditions":"Alcohol Dependence, in Remission, Addiction, Alcohol","enrollment":152},{"nctId":"NCT03167411","phase":"PHASE1","title":"Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection","status":"COMPLETED","sponsor":"Theracos","startDate":"2017-05-24","conditions":"Type2 Diabetes Mellitus","enrollment":20},{"nctId":"NCT02119819","phase":"PHASE2","title":"A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes","status":"COMPLETED","sponsor":"OPKO Health, Inc.","startDate":"2014-04","conditions":"Diabetes Mellitus, Type 2","enrollment":420},{"nctId":"NCT02685852","phase":"PHASE1","title":"Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2016-02","conditions":"Hyperinsulinemic Hypoglycemia","enrollment":11},{"nctId":"NCT04269642","phase":"PHASE2","title":"SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease","status":"UNKNOWN","sponsor":"Peptron, Inc.","startDate":"2020-03-19","conditions":"Early Parkinson's Disease","enrollment":99},{"nctId":"NCT03671733","phase":"PHASE3","title":"Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients","status":"UNKNOWN","sponsor":"Xiangya Hospital of Central South University","startDate":"2018-09-01","conditions":"Obesity","enrollment":150},{"nctId":"NCT00566813","phase":"PHASE1, PHASE2","title":"Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2004-11","conditions":"Diabetes Mellitus, Type 1","enrollment":10},{"nctId":"NCT04027023","phase":"PHASE4","title":"Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Sciema UG","startDate":"2019-10-30","conditions":"Diabetes Mellitus, Type 2","enrollment":9}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["synthetic exendin-4","Exenatide"],"phase":"phase_3","status":"active","brandName":"AC2993","genericName":"AC2993","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AC2993 is a dual GLP-1/GIP receptor agonist that activates both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors to improve glycemic control and promote weight loss. Used for Type 2 diabetes mellitus, Obesity or weight management.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}